Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Nanotelesa : alternativa klasičnim monoklonskim protitelesom
Authors:ID Babič, Davor (Author)
ID Čurin-Šerbec, Vladka (Author)
ID Jovchevska, Ivana (Author)
Files:.pdf PDF - Presentation file, download (1,62 MB)
MD5: 1732772B055E98E189D0A350D96A1C01
 
Language:Slovenian
Typology:1.02 - Review Article
Organization:Logo SFD - Slovenian Pharmaceutical Society
Abstract:Težkoverižna protitelesa, prvič odkrita pri kamelidih leta 1989, predstavljajo nekonvencionalno obliko protiteles, sestavljeno izključno iz težkih verig in brez lahkih verig, značilnih za klasična protitelesa. Njihova posamezna variabilna domena, imenovana nanotelo ima ključne prednosti pred konvencionalnimi protitelesi: stabilnost, manjša velikost, visoka topnost v vodi, boljše prehajanje v tkiva in enostavna proizvodnja v rekombinantnih sistemih. Nanotelesa raziskujejo predvsem na področju diagnostike, kjer se uporabljajo v tehnikah, kot so pozitronska emisijska tomografija s hkratno računalniško tomografijo, biosenzorji in imunokromatografski testi. V terapevtske namene jih razvijajo za zdravljenje raka ter infekcijskih in avtoimunskih bolezni. Od prve odobritve kaplacizumaba leta 2018 so bila odobrena še tri zdravila na osnovi nanoteles, kar potrjuje njihov vse večji pomen v translacijski in klinični medicini.
Keywords:kaplacizumab, monoklonska protitelesa, nanotelesa, PET/CT, rak (medicina)
Publication status:Published
Publication version:Version of Record
Publication date:01.03.2026
Year of publishing:2026
Number of pages:str. 63-73
Numbering:Letn. 77, št. 1
PID:20.500.12556/DiRROS-31030 New window
UDC:615
ISSN on article:0014-8229
COBISS.SI-ID:273357059 New window
Note:Besedilo v slov.;
Publication date in DiRROS:10.07.2026
Views:83
Downloads:42
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Farmacevtski vestnik : strokovno glasilo slovenske farmacije
Shortened title:Farm. vestn.
Publisher:Slovensko farmacevtsko društvo
ISSN:0014-8229
COBISS.SI-ID:3105794 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0390-2022
Name:Funkcijska genomika in biotehnologija za zdravje

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:01.01.2025

Secondary language

Language:English
Title:Nanobodies : an alternative to conventional monoclonal antibodies
Abstract:heavy-chain antibodies, first discovered in camelids in 1989, represent an unconventional form of antibodies composed solely of heavy chains and lacking the light chains that are characteristic for classical antibodies. Their single variable domain, known as a nanobody offers key advantages over conventional antibodies, such as stability, smaller size, high solubility in water, improved tissue penetration, and easy production in recombinant systems. Nanobodies are primarily explored in the field of diagnostics, where they are used in techniques such as positron emission tomography/computed tomography, biosensors, and immunochromatographic tests. For therapeutic purposes, they are being developed for the treatment of cancer as well as infectious and autoimmune diseases. Since the first approval of caplacizumab in 2018, three additional nanobody-based drugs have been approved, confirming their growing importance in translational and clinical medicine.
Keywords:caplacizumab, monoclonal antibodies, nanobodies, cancer, PET/CT


Back